Kindred Biosciences Stock Price, News & Analysis (NASDAQ:KIN)

$7.59
-0.11 (-1.43 %)
(As of 09/23/2019 07:19 AM ET)
Today's Range
$7.50
Now: $7.59
$7.79
50-Day Range
$6.96
MA: $7.39
$8.56
52-Week Range
$5.96
Now: $7.59
$15.11
Volume154,586 shs
Average Volume153,405 shs
Market Capitalization$296.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.47
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.97 million
Book Value$2.69 per share

Profitability

Net Income$-49,690,000.00
Net Margins-1,583.00%

Miscellaneous

Employees146
Market Cap$296.47 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.


Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) issued its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.01. The biopharmaceutical company earned $1.24 million during the quarter, compared to the consensus estimate of $1.97 million. Kindred Biosciences had a negative net margin of 1,583.00% and a negative return on equity of 55.46%. View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

8 analysts have issued twelve-month price targets for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' share price to reach $14.8125 in the next year. This suggests a possible upside of 95.2% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

What is the consensus analysts' recommendation for Kindred Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

What are Wall Street analysts saying about Kindred Biosciences stock?

Here are some recent quotes from research analysts about Kindred Biosciences stock:
  • 1. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (9/18/2019)
  • 2. HC Wainwright analysts commented, "We believe a pivotal study for KIND-016 could be similar in design and size to the pivotal study of lokivetmab (Cytopoint, marketed by Zoetis (ZTS; not rated)), an anti-IL31 antibody approved for the treatment of allergic or atopic dermatitis in dogs. The 274-dog pivotal study of lokivetmab evaluated lokivetmab’s non-inferiority compared to an active control, cyclosporine. In this study, lokivetmab achieved mean percentage PVAS reductions of 42.25, 56.86, and 67.38% on weeks 2, 4, and 8, respectively. We note that despite the positive top-line data of KIND-106, it is difficult to compare the KIND-106 efficacy to that of lokivetmab until the company has disclosed the baseline results and we see the full analysis of the complete data." (7/31/2019)
  • 3. Cantor Fitzgerald analysts commented, "We believe KIN’s pipeline of novel animal health drugs will drive long-term shareholder value. As KIN advances its pipeline, we think investors should begin to appreciate the peak revenue potential of the products the company brings to market. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $25 price target. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $25 price target." (4/26/2019)

Has Kindred Biosciences been receiving favorable news coverage?

News articles about KIN stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX), Cara Therapeutics (CARA), Opko Health (OPK), TherapeuticsMD (TXMD), Celgene (CELG), Corbus Pharmaceuticals (CRBP) and Global Blood Therapeutics (GBT).

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
  • Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.13%), Morgan Stanley (4.87%), Vanguard Group Inc. (4.38%), Renaissance Technologies LLC (3.04%), General American Investors Co. Inc. (1.27%) and Allianz Asset Management GmbH (1.11%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which major investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Granite Investment Partners LLC, Connor Clark & Lunn Investment Management Ltd., BNP Paribas Arbitrage SA and Wells Fargo & Company MN. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Which major investors are buying Kindred Biosciences stock?

KIN stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Allianz Asset Management GmbH, General American Investors Co. Inc., Parametric Portfolio Associates LLC, Vanguard Group Inc., Aperio Group LLC and Gabelli Funds LLC. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $7.59.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $296.47 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is http://kindredbio.com/.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  294 (Vote Underperform)
Total Votes:  590
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel